IGC Pharma
IGC
IGC Pharma (IGC) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Dec 31, 2024
- EPS actual
- −$0.02
- EPS estimate
- −$0.03
- EPS surprise
- +33.33%
- Revenue surprise
- +25.98%
- Revenue
- $257,000.00
- Revenue estimate
- $204,000.00
- Reported
- Feb 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Feb 14, 2025 | −$0.03 | −$0.02 | +33.33% | $257,000.00 | SEC |
| Q2 2025 | Nov 12, 2024 | −$0.03 | −$0.02 | +33.33% | $412,000.00 | SEC |
| Q1 2025 | Aug 7, 2024 | −$0.03 | −$0.03 | +0.00% | $272,000.00 | SEC |
| Q4 2024 | Jun 24, 2024 | −$0.04 | −$0.04 | +12.50% | $295,000.00 | SEC |
| Q3 2024 | Feb 14, 2024 | −$0.04 | −$0.09 | −125.00% | $204,000.00 | SEC |
| Q2 2024 | Nov 9, 2023 | $0.00 | −$0.05 | +0.00% | $300,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did IGC Pharma (IGC) last report earnings?
IGC Pharma last reported on Feb 14, 2025, covering fiscal Q3 2025.
Did IGC beat earnings estimates?
Yes. IGC Pharma reported EPS of −$0.02 for Q3 2025 against a −$0.03 estimate — a 33.33% beat.
How much revenue did IGC report last quarter?
IGC Pharma reported $257,000.00 in revenue for Q3 2025, against a consensus estimate of $204,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.